316 related articles for article (PubMed ID: 18945688)
1. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Kristal AR; Schenk JM; Song Y; Arnold KB; Neuhouser ML; Goodman PJ; Lin DW; Stanczyk FZ; Thompson IM
Am J Epidemiol; 2008 Dec; 168(12):1416-24. PubMed ID: 18945688
[TBL] [Abstract][Full Text] [Related]
2. Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.
Kristal AR; Till C; Tangen CM; Goodman PJ; Neuhouser ML; Stanczyk FZ; Chu LW; Patel SK; Thompson IM; Reichardt JK; Hoque A; Platz EA; Figg WD; Van Bokhoven A; Lippman SM; Hsing AW
Cancer Epidemiol Biomarkers Prev; 2012 Oct; 21(10):1823-32. PubMed ID: 22879203
[TBL] [Abstract][Full Text] [Related]
3. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of sex hormone levels and risk of prostate cancer.
Gann PH; Hennekens CH; Ma J; Longcope C; Stampfer MJ
J Natl Cancer Inst; 1996 Aug; 88(16):1118-26. PubMed ID: 8757191
[TBL] [Abstract][Full Text] [Related]
5. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
Schenk JM; Kristal AR; Neuhouser ML; Tangen CM; White E; Lin DW; Thompson IM
Prostate; 2009 Sep; 69(12):1303-11. PubMed ID: 19475640
[TBL] [Abstract][Full Text] [Related]
6. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial.
Chen C; Weiss NS; Stanczyk FZ; Lewis SK; DiTommaso D; Etzioni R; Barnett MJ; Goodman GE
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1410-6. PubMed ID: 14693730
[TBL] [Abstract][Full Text] [Related]
7. Hormone blood levels and their inter-relationships in normal men and men with benign prostatic hyperplasia (BPH).
Bartsch W; Becker H; Pinkenburg FA; Krieg M
Acta Endocrinol (Copenh); 1979 Apr; 90(4):727-36. PubMed ID: 86267
[TBL] [Abstract][Full Text] [Related]
8. Endogenous sex hormones and the risk of prostate cancer: a prospective study.
Weiss JM; Huang WY; Rinaldi S; Fears TR; Chatterjee N; Hsing AW; Crawford ED; Andriole GL; Kaaks R; Hayes RB
Int J Cancer; 2008 May; 122(10):2345-50. PubMed ID: 18172860
[TBL] [Abstract][Full Text] [Related]
9. Serum steroids in relation to benign prostatic hyperplasia.
Lagiou P; Mantzoros CS; Tzonou A; Signorello LB; Lipworth L; Trichopoulos D
Oncology; 1997; 54(6):497-501. PubMed ID: 9394847
[TBL] [Abstract][Full Text] [Related]
10. Circulating steroid hormones and the risk of prostate cancer.
Severi G; Morris HA; MacInnis RJ; English DR; Tilley W; Hopper JL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jan; 15(1):86-91. PubMed ID: 16434592
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of sex hormones in men with severe lower urinary tract symptoms and benign prostatic hyperplasia.
Tan MO; Karabiyik I; Uygur MC; Diker Y; Erol D
Int Urol Nephrol; 2003; 35(3):357-63. PubMed ID: 15160539
[TBL] [Abstract][Full Text] [Related]
12. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
13. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
Kristal AR; Price DK; Till C; Schenk JM; Neuhouser ML; Ockers S; Lin DW; Thompson IM; Figg WD
Prostate; 2010 May; 70(6):584-90. PubMed ID: 19938041
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of follicle stimulating hormone, luteinizing hormone, prolactin, testosterone, 5 alpha-dihydrotestosterone, 5 alpha-androstane-3 alpha, 17 beta-diol, 5 alpha-androstane-3 beta, 17 beta-diol, and 17 beta-estradiol from male beagles with spontaneous or induced benign prostatic hyperplasia.
Cochran RC; Ewing LL; Niswender GD
Invest Urol; 1981 Nov; 19(3):142-7. PubMed ID: 6170603
[TBL] [Abstract][Full Text] [Related]
16. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.
Schenk JM; Kristal AR; Arnold KB; Tangen CM; Neuhouser ML; Lin DW; White E; Thompson IM
Am J Epidemiol; 2011 Jun; 173(12):1419-28. PubMed ID: 21540324
[TBL] [Abstract][Full Text] [Related]
17. Finasteride reduces the risk of incident clinical benign prostatic hyperplasia.
Parsons JK; Schenk JM; Arnold KB; Messer K; Till C; Thompson IM; Kristal AR; ;
Eur Urol; 2012 Aug; 62(2):234-41. PubMed ID: 22459892
[TBL] [Abstract][Full Text] [Related]
18. Relationship between serum sex hormones levels and degree of benign prostate hyperplasia in Chinese aging men.
Zeng QS; Xu CL; Liu ZY; Wang HQ; Yang B; Xu WD; Jin TL; Wu CY; Huang G; Li Z; Wang B; Sun YH
Asian J Androl; 2012 Sep; 14(5):773-7. PubMed ID: 22751417
[TBL] [Abstract][Full Text] [Related]
19. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Kristal AR; Arnold KB; Schenk JM; Neuhouser ML; Goodman P; Penson DF; Thompson IM
Am J Epidemiol; 2008 Apr; 167(8):925-34. PubMed ID: 18263602
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Schenk JM; Kristal AR; Neuhouser ML; Tangen CM; White E; Lin DW; Kratz M; Thompson IM
Am J Epidemiol; 2010 Mar; 171(5):571-82. PubMed ID: 20142396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
